Clinical Trials Browser

OTHER × Carcinoma, Non-Small-Cell Lung × Ramucirumab × Clear all

NCT03909334 2026-04-17

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06007937 2026-04-08

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT03527108 2026-01-14

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04332367 2026-01-07

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04120454 2025-07-11

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

6 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03689855 2024-07-30

RamAtezo-1

Phase 2 Completed

21 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03904108 2022-05-26

Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

Phase 2 Terminated

3 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung

NCT04040361 2022-04-06

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05007769 2021-11-05

RAN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02730247 2020-11-19

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

7 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung